Journal: The EMBO Journal
Article Title: LC3-associated phagocytosis of neutrophils triggers tumor ferroptotic cell death in glioblastoma
doi: 10.1038/s44318-024-00130-4
Figure Lengend Snippet: ( A ) Schematic detailing the unbiased drug screen. Luciferase readouts of cocultured wells were normalized to their respective monocultured wells, both in the presence of the tested drug (2 µM), to determine the relative viability. ( B ) Dataset summarizing the results of the unbiased drug screen. Relative viabilities of each drug were normalized to the DMSO control groups. ( C ) Cancer cell viability determined using luciferase readouts for LN229 TAZ(4SA) cells cocultured with dHL-60 cells with DMSO, simvastatin (2.5 µM), or fluvastatin (2.5 µM). Luminescence readouts of cocultured wells were normalized to their respective LN229 TAZ(4SA) cells monocultured wells, both with drugs ( n = 3 independent experiments), one-way ANOVA. ( D ) Diagram summarizing the MVA pathway and the targets of drugs tested. ( E ) Luciferase assay results for LN229 TAZ(4SA) cells cocultured with dHL-60 cells with GGTI-298 ( n = 3 independent experiments). Luminescence readouts of cocultured wells were normalized to their respective LN229 TAZ(4SA) cells monocultured wells, both with drugs. One-way ANOVA. ( F ) Cancer cell viability determined using luciferase readouts for LN229 TAZ(4SA) cells cocultured with TAN with DMSO, simvastatin (2.5 µM), or fluvastatin (2.5 µM). Luminescence readouts of cocultured wells were normalized to their respective LN229 TAZ(4SA) cells monocultured wells, both with drugs ( n = 3 independent experiments), one-way ANOVA. ( G ) Luciferase assay results for LN229 TAZ(4SA) cells cocultured with TAN with GGTI-298 (10 µM) and YM-53691 (10 µM) ( n = 3 independent experiments). Luminescence readouts of cocultured wells were normalized to their respective LN229 TAZ(4SA) cells monocultured wells, both with drugs. One-way ANOVA. ( H , I ) Cell death evaluated using YOYO-3 Iodide stain for LN229 TAZ(4SA) cells cultured with ( H ) IKE (0.75 µM) or ( I ) RSL3 (0.125 µM) with DMSO, fluvastatin (2.5 µM), simvastatin (2.5 µM), GGTI-298 (5 µM), YM-53601 (10 µM), or FTI-277 (10 µM) ( n = 3 independent experiments), one-way ANOVA. ( J ) Representative images showing immunofluorescent PKH26, MPO and DAPI signal for LN229 TAZ(4SA) cells cocultured with PKH26-labeled dHL-60 cells with DMSO, simvastatin (5 µM), fluvastatin (5 µM), GGTI-298 (10 µM), or YM-53601 (10 µM) ( n = 3). Scale bar, 10 µm. ( K ) Quantification of MPO puncta in each tumor cell in the experiments as shown in ( J ). Two fields of view were used for each group in each experiment ( n = 3 independent experiments). One-way ANOVA. ( L ) Quantification of PKH26 puncta in each tumor cell in the experiments as shown in ( J ). Two fields of view used for each group in each experiment ( n = 3 independent experiments). One-way ANOVA. Error bars, s.e.m. .
Article Snippet: Compounds used to treat cells: Prestwick Chemical FDA Library (provided by the Drug Discovery, Development and Delivery core of PSU College of Medicine), simvastatin (10010344, Cayman Chemicals), fluvastatin (10010334, Cayman Chemicals), GGTI-298 (16176, Cayman Chemicals), YM-53601 (18113, Cayman Chemicals), FTI-277 (S7465, SelleckChem), RGDS (A9041, Sigma-Aldrich), Vps34-IN1 (17392, Cayman Chemicals), Liproxstatin-1 (SML1414, Sigma), 4-Aminobenzoic hydrazide (4-ABHA, 103200050, Acros Organics), IKE (S8877, SelleckChem), RSL3 (19288, Cayman Chemicals).
Techniques: Luciferase, Control, Staining, Cell Culture, Labeling